MedTrace Logo

Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)

NCT00000136 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2015-10-22

Study results available
· View outcomes & findings →

Summary

To evaluate the relative safety and efficacy of ganciclovir and foscarnet as initial treatment of patients with cytomegalovirus (CMV) retinitis.

Conditions

  • HIV Infections
  • Cytomegalovirus Retinitis

Interventions

DRUG

Foscarnet

60 mg/kg every 8 hours, 90 mg/kg/day

DRUG

Ganciclovir

5 mg/kg every 12 hours, 5 mg/kg every 24 hours

Sponsors & Collaborators

Principal Investigators

  • Curtis Meinert, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1990-03-31
Primary Completion
1991-10-31
Completion
1991-10-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000136 on ClinicalTrials.gov